5:55 PM
 | 
Oct 28, 2010
 |  BC Extra  |  Financial News

Lovenox sales decline

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said third quarter sales of Lovenox enoxaparin fell 26% to EUR 537 million ($732 million) compared to 3Q09 due to generic competition for the anticoagulant. Last week, Novartis AG (NYSE:NVS; SIX:NOVN) reported $292 million in 3Q10 sales for its generic version of...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >